Skip to main content
OpenTrials
Completed

NCT Number: NCT05213442

Liver Status in Psychiatric Inpatients

Adults hospitalized in psychiatry have an increased frequency of somatic disorders, in particular various liver diseases (viral hepatitis, non-alcohol related liver steatosis, alcohol related liver disease).

The evaluation of these liver disorders in psychiatric inpatients remains very little explored in France, contributing to the poor overall medical status of psychiatric patients.

The LIVERSPIN study aims to estimate the prevalence rates of liver pathologies in psychiatric inpatients and to explore the factors associated with the existence of a liver pathology

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psychiatric Illness Mental Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Le Vinatier

Bron, Auvergne-Rhône-Alpes, 69678 cedex, France

About this study

The LIVERSPIN study aims to estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.

All hospitalized patients can potentially be recruited. They will benefit from the usual clinical and paraclinical examinations as part of their hospitalization diagnostic work-up. For the determination of biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years old
  • Social insurance
  • Current hospitalization in any psychiatric unit of the participating center
  • Adult or legal representative who has given written and informed consent to participate in the study. By default, the oral consent of the adult will be obtained (as well as the written consent of the legal representative)
  • Information given to the curator(for people under curatorship)

Exclusion criteria

  • - Clinical state of the patient which do not allow the collection of study data (according to the investigator)

Treatment and study plan

To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.

Diagnostic Test

Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.

Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires).

Primary outcomes

  1. HCV diagnosis

    Time frame: At inclusion

    HCV diagnosis defined by positive HCV antibodies in blood

Secondary outcomes

  1. HBV diagnosis

    Time frame: At inclusion

    HBV diagnosis defined by positive HBsAg in blood

  2. HIV diagnosis

    Time frame: At inclusion

    HIV diagnosis defined by positive anti-HIV1 or anti-HIV2 antibodies in blood

  3. Suspicion of NAFLD

    Time frame: At inclusion

    Suspicion of NAFLD on FIB-4 and the interrogation

  4. Suspicion of alcoholic liver disease

    Time frame: At inclusion

    Suspicion of alcoholic liver disease on FIB-4 and the interrogation

Sponsors and collaborators

Lead sponsor

Hôpital le Vinatier

Other

Collaborators

  • Hospices Civils de Lyon

Registry information

Acronym: LIVERSPIN

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jan 28, 2022
Registry last updated
Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.